Lung Disease Therapeutics Market

Lung Disease Therapeutics Market (Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, and Other Lung Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Lung Disease Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 76.5 Bn in 2021
  • It is projected to grow at a CAGR of 3.7% from 2022 to 2031 and reach more than US$ 109.4 Bn by the end of 2031

Analysts’ Viewpoint

Lung disease therapeutics, such as drugs, are used to treat various lung diseases. High incidence and prevalence of Chronic Obstructive Pulmonary Disease (COPD) and rise in awareness programs are driving the global lung disease therapeutics market. Ongoing research & development activities and launch of products for the treatment of COPD are fueling market expansion. Advancements in technology, such as development of biologic therapies, are expected to augment market progress in the near future.

Development of new approaches in therapeutic agent delivery, vaccine development, and nanotechnology-based medical detections are likely to present lucrative opportunities to market players. Companies are focusing on developing new drugs and treatments to improve treatment options for patients with lung disease.

Lung Disease Therapeutics Market

Lung Disease Therapeutics Market Introduction

Lung disease therapeutics include a range of drugs and treatments used to manage various lung conditions, including asthma, COPD, lung cancer, and idiopathic pulmonary fibrosis (IPF). The market is driven by factors such as rise in aging population, increase in rate of smoking, growth in air pollution, and surge in awareness about lung diseases.

Some respiratory diseases are acute, such as an infection, and improve with treatment. Other diseases are chronic and must be managed. Chronic respiratory conditions can be caused by various lung diseases. Millions of people in the U.S. suffer from chronic respiratory diseases. Lung diseases are classified into specific conditions; hence, it is difficult to estimate how many people suffer from them.

Asthma is the largest segment of the lung disease therapeutics market, due to its high prevalence and the need for ongoing treatment and management. Asthma affects 24.8 million people in the U.S., including 5.5 million children, and is responsible for millions of emergency department visits and tens of billions of dollars in healthcare costs each year.

Request a sample to get extensive insights into the Lung Disease Therapeutics Market

Rise in Prevalence of Lung Cancer

Increase in prevalence of lung cancer is a key driver of lung disease therapeutics market growth. It is the leading cause of cancer-related deaths globally, with a projected 1.8 million deaths per year. Incidence of the disease is expected to rise in the next few years. Development of new treatments, such as immunotherapies and targeted therapies, has improved the survival rate and management of lung cancer patients.

Lung cancer is the second most common cancer in both men and women in the U.S., with an estimated 228,820 new cases and 135,720 deaths in 2021. The five-year survival rate for lung cancer is 18%, which is lower than many other types of cancer.

Increase in adoption of screening and early detection methods are expected to contribute to market growth in the next few years. Rise in sophistication in treatment and management of lung cancer is also anticipated to augment market expansion.

Development of Robust Clinical Trial Pipeline by Key Players

Increase in incidence of COPD and rich clinical trial pipeline for new treatments are projected to boost lung disease therapeutics market size. COPD is a major public health concern due to high prevalence and significant impact on quality of life and mortality. Development of new treatments, such as biologics and targeted therapies, is estimated to improve the management of COPD and other lung diseases, leading to an increase in demand for these products. Additionally, the market is expected to benefit from the development of new indications for existing therapies and introduction of new combination therapies.

Leading COPD companies, such as Sanofi, United Therapeutics Corporation, AstraZeneca, Verona Pharma plc, Novartis, Genentech, and Vertex Pharmaceuticals, are focusing on developing new molecules. In September 2021, Renovion and the COPD Foundation announced a new partnership to accelerate the development of a novel therapy for the treatment of excessive airway mucus and inflammation in people with COPD and non-cystic fibrosis (CF) bronchiectasis.

Request a custom report on Lung Disease Therapeutics Market

Need for Ongoing Treatment and Management of Asthma

In terms of disease type, the asthma segment accounted for significant global lung disease therapeutics market share in 2021. Asthma is a chronic lung disease that affects the airways, making it difficult to breathe. It is characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and shortness of breath.

High prevalence and the need for ongoing treatment & management can be ascribed to the large market share of the segment. Different types of medication, including inhaled corticosteroids, beta-agonists, and leukotriene modifiers, are used to manage asthma symptoms and prevent exacerbations.

Highly Effective and Safe Treatment

Based on drug class, the corticosteroids segment led the global lung disease therapeutics market in 2021. Corticosteroids are a class of drugs commonly used to treat lung diseases such as asthma and COPD. These drugs reduce inflammation in the airways, which helps improve breathing.

High effectiveness can be ascribed to the corticosteroids segment's significant share of the lung disease therapeutics market. These drugs are widely used in the treatment of various lung diseases and have been proven to be safe and effective. Therefore, they are often prescribed as first-line therapy for several lung diseases.

The bronchodilators segment held the second-largest share of the market in 2021. Bronchodilator is a type of medication that makes breathing easier. It relaxes the muscles in the lungs and widens the airways. This drug class is used to treat long-term conditions such as asthma and COPD.

Availability of Wide Range of Medications in Hospital Pharmacies

In terms of distribution channel, the hospital pharmacies segment dominated the global lung disease therapeutics industry in 2021. Hospital pharmacies are responsible for supplying and dispensing medications to inpatients. Thus, they play a critical role in the management of lung diseases such as COPD and asthma.

Hospital pharmacies have access to a range of medications, including specialized therapeutics for lung diseases. These pharmacies are staffed by trained pharmacists who provide expert advice on medication usage and management. Hospital pharmacies are closely connected to other healthcare professionals such as doctors and nurses, leading to better coordination of care and improved patient outcomes.

Hospital pharmacies have the infrastructure and resources to handle complex medication regimens and manage potential drug interactions or adverse reactions. They also play a key role in monitoring and managing the usage of antibiotics, which are often prescribed for lung infection treatment.

Regional Outlook of Global Lung Disease Therapeutics Market

North America accounted for the largest share in 2021. The region has a well-established market and advanced healthcare systems. Market players are making significant investments in research & development activities in the region. Furthermore, high prevalence of lung diseases, such as COPD and asthma, is driving market statistics in North America.

Emerging markets in Asia Pacific and Latin America have less investment in the lung disease therapeutics industry and low prevalence of lung diseases. However, these regions are likely to witness significant market development in the next few years due to improvement in healthcare systems and increase in prevalence of lung diseases.

As per lung disease therapeutics market analysis, Middle East & Africa held small share in 2021. The market in the region is expected to experience robust growth during the forecast period. This can be ascribed to the increase in efforts to improve healthcare infrastructure and rise in patient access to treatment.

Analysis of Key Players

Expansion of product portfolio and merger & acquisition are the key strategies adopted by prominent manufacturers in the global lung disease therapeutics market. GSK, AstraZeneca, Boehringer Ingelheim, IQVIA, Novartis, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, and PharmAkea Therapeutics are the prominent players in the market.

Key Developments in Global Lung Disease Therapeutics Market

  • In August 2022, AstraZeneca India announced a collaboration with Alveofit to provide IoT-enabled handheld spirometers in hospitals across the country. According to the vaccine manufacturer, this collaboration aims to incorporate the most recent technological advances in diagnosing and managing lung disorders and associated non-communicable diseases such as asthma, pulmonary fibrosis, and COPD.
  • In July 2021, BREATHE and IQVIA announced a partnership to accelerate the early diagnosis and treatment of respiratory conditions. With clear strategic alignment, IQVIA joined BREATHE as a Supporting Partner to work together to improve health outcomes and quality of life for people living with respiratory conditions in the U.K.
  • In November 2020, Bridge Biotherapeutics, Inc. and Boehringer Ingelheim International GmbH ended their collaboration on the experimental therapy BBT-877 for a type of lung disease. Bridge Biotherapeutics, Inc. will regain all rights to BBT-877, which is being developed to treat idiopathic pulmonary fibrosis and other fibrotic diseases.

The lung disease therapeutics market report profiles key players based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Lung Disease Therapeutics Market Snapshot

Attribute

Detail

Size in 2021

US$ 76.5 Bn

Forecast (Value) in 2031

More than US$ 109.4 Bn

Growth Rate (CAGR)

3.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Disease Type
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Other Lung Diseases
  • Drug Class
    • Corticosteroids
    • Bronchodilator Medications
    • Mucolytics
    • Antimicrobial Medications
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Mylan
  • Vertex Pharmaceuticals
  • F. Hoffman La Roche
  • Teva Pharmaceuticals
  • Cipla
  • Fibrogen
  • Liminal Biosciences
  • PharmAkea Therapeutics
  • IQVIA

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global lung disease therapeutics market in 2021?

The industry was valued at US$ 76.5 Bn in 2021.

How big will it be in 2031?

It is projected to reach more than US$ 109.4 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 3.7% from 2022 to 2031.

Which are the prominent trends that affect growth?

Rise in prevalence of chronic obstructive pulmonary disease (COPD) & asthma and increase in number of cases of lung cancer.

Which region will account for major share during the forecast period?

North America is projected to account for significant share during the forecast period.

Who are the prominent players in the sector?

GSK, AstraZeneca, IQVIA, Boehringer Ingelheim, Novartis, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, and PharmAkea Therapeutics.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Lung Disease Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Drug Pipeline Analysis

        5.3. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.4. Regulatory Scenario by Region/Globally

        5.5. COVID-19 Impact Analysis

    6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Disease Type, 2017–2031

            6.3.1. Asthma

            6.3.2. Chronic Obstructive Pulmonary Disease (COPD)

            6.3.3. Lung Cancer

            6.3.4. Others

        6.4. Market Attractiveness Analysis, by Disease Type

    7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Drug Class, 2017–2031

            7.3.1. Corticosteroids

            7.3.2. Bronchodilator Medications

            7.3.3. Mucolytics

            7.3.4. Antimicrobial Medications

            7.3.5. Others

        7.4. Market Attractiveness Analysis, by Drug Class

    8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Lung Disease Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Disease Type, 2017–2031

            10.2.1. Asthma

            10.2.2. Chronic Obstructive Pulmonary Disease (COPD)

            10.2.3. Lung Cancer

            10.2.4. Others

        10.3. Market Value Forecast, by Drug Class, 2017–2031

            10.3.1. Corticosteroids

            10.3.2. Bronchodilator Medications

            10.3.3. Mucolytics

            10.3.4. Antimicrobial Medications

            10.3.5. Others

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Disease Type

            10.6.2. By Drug Class

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Lung Disease Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Disease Type, 2017–2031

            11.2.1. Asthma

            11.2.2. Chronic Obstructive Pulmonary Disease (COPD)

            11.2.3. Lung Cancer

            11.2.4. Others

        11.3. Market Value Forecast, by Drug Class, 2017–2031

            11.3.1. Corticosteroids

            11.3.2. Bronchodilator Medications

            11.3.3. Mucolytics

            11.3.4. Antimicrobial Medications

            11.3.5. Others

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Disease Type

            11.6.2. By Drug Class

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Disease Type, 2017–2031

            12.2.1. Asthma

            12.2.2. Chronic Obstructive Pulmonary Disease (COPD)

            12.2.3. Lung Cancer

            12.2.4. Others

        12.3. Market Value Forecast, by Drug Class, 2017–2031

            12.3.1. Corticosteroids

            12.3.2. Bronchodilator Medications

            12.3.3. Mucolytics

            12.3.4. Antimicrobial Medications

            12.3.5. Others

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Disease Type

            12.6.2. By Drug Class

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Lung Disease Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Disease Type, 2017–2031

            13.2.1. Asthma

            13.2.2. Chronic Obstructive Pulmonary Disease (COPD)

            13.2.3. Lung Cancer

            13.2.4. Others

        13.3. Market Value Forecast, by Drug Class, 2017–2031

            13.3.1. Corticosteroids

            13.3.2. Bronchodilator Medications

            13.3.3. Mucolytics

            13.3.4. Antimicrobial Medications

            13.3.5. Others

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Disease Type

            13.6.2. By Drug Class

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Disease Type, 2017–2031

            14.2.1. Asthma

            14.2.2. Chronic Obstructive Pulmonary Disease (COPD)

            14.2.3. Lung Cancer

            14.2.4. Others

        14.3. Market Value Forecast, by Drug Class, 2017–2031

            14.3.1. Corticosteroids

            14.3.2. Bronchodilator Medications

            14.3.3. Mucolytics

            14.3.4. Antimicrobial Medications

            14.3.5. Others

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of MEA

        14.6. Market Attractiveness Analysis

            14.6.1. By Disease Type

            14.6.2. By Drug Class

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company (2021)

        15.3. Company Profiles

            15.3.1. GSK

                15.3.1.1. Company Overview

                15.3.1.2. Disease Type Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. AstraZeneca

                15.3.2.1. Company Overview

                15.3.2.2. Disease Type Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Boehringer Ingelheim

                15.3.3.1. Company Overview

                15.3.3.2. Disease Type Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Novartis

                15.3.4.1. Company Overview

                15.3.4.2. Disease Type Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Vertex Pharmaceuticals

                15.3.5.1. Company Overview

                15.3.5.2. Disease Type Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. F. Hoffman La Roche

                15.3.6.1. Company Overview

                15.3.6.2. Disease Type Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Teva Pharmaceuticals

                15.3.7.1. Company Overview

                15.3.7.2. Disease Type Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Cipla

                15.3.8.1. Company Overview

                15.3.8.2. Disease Type Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Liminal Biosciences

                15.3.9.1. Company Overview

                15.3.9.2. Disease Type Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. Fibrogen

                15.3.10.1. Company Overview

                15.3.10.2. Disease Type Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

            15.3.11. PharmAkea Therapeutics

                15.3.11.1. Company Overview

                15.3.11.2. Disease Type Portfolio

                15.3.11.3. SWOT Analysis

                15.3.11.4. Financial Overview

                15.3.11.5. Strategic Overview

            15.3.12. IQVIA

                15.3.12.1. Company Overview

                15.3.12.2. Disease Type Portfolio

                15.3.12.3. SWOT Analysis

                15.3.12.4. Financial Overview

                15.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 02: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 03: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 07: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 08: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 11: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 15: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 16: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 19: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 20: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 23: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 24: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Lung Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

    Figure 02: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Disease Type, 2021

    Figure 03: Global Lung Disease Therapeutics Market Value Share, by Disease Type, 2021

    Figure 04: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2021

    Figure 05: Global Lung Disease Therapeutics Market Value Share, by Drug Class, 2021

    Figure 06: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2021

    Figure 07: Global Lung Disease Therapeutics Market Value Share, by Distribution Channel, 2021

    Figure 08: Global Lung Disease Therapeutics Market Value Share, by Region, 2021

    Figure 09: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 10: Global Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 11: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031

    Figure 12: Global Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 13: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031

    Figure 14: Global Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 15: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031

    Figure 16: Global Lung Disease Therapeutics Market Value Share Analysis, by Region, 2017 and 2031

    Figure 17: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031

    Figure 18: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2031

    Figure 20: North America Lung Disease Therapeutics Market Value Share Analysis, by Country, 2017 and 2031

    Figure 21: North America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 22: North America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 23: North America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 24: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 25: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 26: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 27: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 29: Europe Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 30: Europe Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 31: Europe Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 32: Europe Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 33: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 34: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 35: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 36: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 38: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 39: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 40: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 41: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 42: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 43: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 44: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 47: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 48: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 49: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 50: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 51: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 52: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 53: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 54: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 56: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 57: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031

    Figure 58: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031

    Figure 59: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 60: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 61: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 62: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved